复方川芎嗪胶囊干预氯吡格雷抵抗的临床研究
摘要
目的评价复方川芎嗪胶囊对氯吡格雷抵抗患者的干预效果。方法采用比浊法测定血小板聚集率,将氯吡格雷抵抗患者68例随机分为两组,氯吡格雷加复方川芎嗪胶囊组及单服氯吡格雷组,每组34例。干预2周后分别复查血小板聚集率。结果干预后氯吡格雷加复方川芎嗪胶囊组二磷酸腺苷(ADP)诱导的血小板聚集率为29.23%,较干预前37.78%下降9.58%(P<0.01);而单用氯吡格雷组干预前后无明显变化(P>0.05)。结论复方川芎嗪胶囊可以增强患者对氯吡格雷的敏感性,降低氯吡格雷抵抗,两药有协同抑制血小板聚集作用。
引文
[1]Savi P,Pereillo JM,Uzabiaga MF,et al.Identification and biological activity of the active metabolite of clopidogrel[J].Thromb Haemost,2000,84(5):891-896.
[2]Paul A,Bliden KP,Hiatt BI,et al.Clopidogrel for coronary stenting:Response variability,drug resist,and the effect of pretreatment platelet reactivity[J].Circulation,2003,107:2908-2913.
[3]谭丽玲,贾三庆,王明生,等.急性冠脉综合征患者氯吡格雷抵抗的影响因素[J].中国心血管病研究杂志,2006,4(9):680-682.
[4]Jarvis B,Simpson K.Clopidogrel:A review of its use in the prevention of atherothrombosis[J].Drugs,2000,60:347-377.
[5]Fontana P,Gaussem P,Aiach M,et al.P2Y12H2haplotype is associated with peripheral arterial disease:A case-control study[J].Circulation,2003,10(24):297l-2973.
[6]陈可冀,李连达,翁维良,等.血瘀证与活血化瘀研究[J].中西医结合心脑血管病杂志,2005,3(1):1-2.
[7]严威,吴小盈,孙红,等.氯吡格雷抵抗与血瘀证关系分析[J].江西中医学院学报,2009,21(5):63-65.
[2]Paul A,Bliden KP,Hiatt BI,et al.Clopidogrel for coronary stenting:Response variability,drug resist,and the effect of pretreatment platelet reactivity[J].Circulation,2003,107:2908-2913.
[3]谭丽玲,贾三庆,王明生,等.急性冠脉综合征患者氯吡格雷抵抗的影响因素[J].中国心血管病研究杂志,2006,4(9):680-682.
[4]Jarvis B,Simpson K.Clopidogrel:A review of its use in the prevention of atherothrombosis[J].Drugs,2000,60:347-377.
[5]Fontana P,Gaussem P,Aiach M,et al.P2Y12H2haplotype is associated with peripheral arterial disease:A case-control study[J].Circulation,2003,10(24):297l-2973.
[6]陈可冀,李连达,翁维良,等.血瘀证与活血化瘀研究[J].中西医结合心脑血管病杂志,2005,3(1):1-2.
[7]严威,吴小盈,孙红,等.氯吡格雷抵抗与血瘀证关系分析[J].江西中医学院学报,2009,21(5):63-65.